[약업신문]CHA Vaccine Research Institute announces development status of ‘Corona 19 Influenza’ combination vaccine

Cha Vaccine Research Institute (CEO Jeong-seon Yeom) announced on the 17th that it was present at the ‘2022 Hwasun International Vaccine Forum’ and presented the development status of a ‘new mixed corona and influenza premium vaccine candidate’.

Te Jeon Eun-young Vaccine Research Institute, Director of Research (Photo) presented on the theme ‘Corona Vaccine Development in the Era of Corona 19 Endemic’ at the ‘Republic of Korea Vaccine Research and Development Sharing Chapter 2022’ session held on the 11th.

The Cha Vaccine Research Institute is developing a candidate substance for a ‘mixed 19-flu Corona vaccine’ with better convenience and preventive effect for the elderly.

Jeon, Assistant Director of Research, said, “This candidate material uses L-pampo™, an immune enhancement platform developed by the DRC Vaccine Research Institute, to simultaneously increase immunogenicity against corona and influenza, and especially for the elderly with reduced immunity. can increase the deterrent effect.”

As a result of his own experiments, L-Fampo, an immune enhancing platform, induced a higher level of immunogenicity than the immune enhancing agents used in commercially available vaccines. Even in the COVID-19-flu combination vaccine, the humoral immune response that activates the production of antibodies against the antigens of both viruses can be activated as well as the cellular immune response that directly attacks the virus to increase vaccine efficiency in the elderly. with reduced immunity, it was confirmed that

Based on these results, the Cha Vaccine Institute’s ‘new premium mixed corona and influenza vaccine candidate’ was selected for the ‘future growth high added value vaccine development’ project conducted by the Ministry of Health and Welfare.

Accordingly, there is demand for the development of a vaccine that can simultaneously respond to both COVID-19 and seasonal influenza. In particular, the COVID-19-flu combination vaccine has the advantage of increasing the convenience of vaccination because it can prevent two diseases at the same time with one vaccination.

As Corona 19 gradually enters endemicity, it is expected to become common every year as a seasonal flu, attracting attention. Recently, a ‘twindemic’ is happening, where the epidemic of the 7th corona19 and the seasonal flu epidemic overlap. In particular, according to recent research results, when infected with influenza, the expression of the receptor for Corona virus 19 increases, and the possibility of infection with Corona virus 19 is high.

However, the elderly are vulnerable to infection as their immunity is low. According to the World Health Organization (WHO), the mortality rate for those aged 60 or over is 0.8% due to seasonal flu and 6% due to Corona 19. Specifically, when infected with Corona 19 and the flu, the death rate was 1.6 times higher than when infected with the flu alone. In particular, current vaccines do not induce adequate vaccine efficacy in the elderly with reduced immune function due to aging.

“CHA Vaccine Research Institute is developing a premium vaccine that exceeds the limits of existing vaccines by utilizing the excellence of its self-developed immune enhancement platform,” said CEO Yum Jeong-seon of CHA Vaccine Research Institute. research activities to ensure international competitiveness.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.